Here is an overview of each medicine to help guide you and your physician when making a treatment decision for Cystic Fibrosis: 
cystic fibrosis
-
Read more »
-
August 16, 2019Read more »
Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.
-
February 28, 2019Read more »
Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years.
-
February 25, 2019Read more »
A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.
